Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | PHASE1 | COMPLETED | 113 | — | — | Sep 1, 2008 | Jun 1, 2013 | Jul 25, 2013 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A-Dose escalation and confirmation | EXPERIMENTAL | - |
| Part B - Prostate/Ovarian Cancer Cohort | EXPERIMENTAL | - |
| Part C - T-PLL/CLL cohort | EXPERIMENTAL | - |
| Part D - CRC, endometrial, breast, and ovarian cancer cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-4827 | DRUG | MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D). |
Inclusion criteria: * For Part A, participants must have a cytologically- or histologically-confirmed metastatic or locally advanced solid tumor for which standard therapy does not exist or the participants have refused standard therapy. * For Part B, participants must have a cytologically- or hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |